Vaxzevria is indicated for the active immunisation of individuals aged 18 year and above for preventing Covid-19. Credit: Bra艌o / Unsplash.

The Ministry of Health, Labour and Welfare (MHLW) of Japan has authorised 鈥檚 Covid-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) and 鈥檚 mRNA Covid-19 vaccine for emergency use in the country.

Vaxzevria聽is indicated for active immunisation of people aged 18 years and above for preventing Covid-19.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Co-developed by the University of Oxford and Vaccitech, Vaxzevria聽is an adenovirus-based vaccine with the SARS-CoV-2 spike protein genetic material.

The MHLW authorisation for Vaxzevria聽is based on positive efficacy and safety results from Phase III trials led by Oxford University in the UK, Brazil and South Africa, as well as a Phase I/II study in Japan.

According to the recommendation of Japan鈥檚 Pharmaceuticals and Medical Devices Agency, two intramuscular 0.5ml doses of Vaxzevria can be administered to adults four to 12 weeks apart.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: 鈥淲e continue to expand global access to our vaccine and today鈥檚 approval brings us one step closer to providing聽Vaxzevria聽to the people of Japan who urgently need protection from coronavirus.

鈥淲e are proud to have produced a vaccine for the world, which is playing a leading role in the global fight against the pandemic, with more than 400 million doses now supplied by AstraZeneca and sub-licensees to 165 countries.鈥�

Vaxzevria聽manufacturing is ongoing in Japan with the first doses to be made available soon.

Formerly known as AZD1222, this vaccine is authorised for emergency use in nearly 80 countries and holds Emergency Use Listing from the World Health Organization (WHO).

The MHLW authorisation For emergency use of Moderna鈥檚 mRNA Covid-19 vaccine, TAK-919, now known as Covid-19 Vaccine Moderna Intramuscular Injection, is based on Phase III COVE trial findings.

In addition, the MHLW considered data from a Phase I/II trial led by , which will commence the vaccine鈥檚 marketing soon.

As per an agreement with Moderna and the MHLW entered in October last year, Takeda is set to distribute 50 million doses of the mRNA vaccine in Japan in the first half of this year.

In a separate development, Moderna and signed a manufacturing service and supply agreement, under which the latter will offer large-scale fill-finish manufacturing for Moderna鈥檚 Covid-19 vaccine in South Korea.